Zurich Cantonal Bank’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
Zurich Cantonal Bank's PTGX Position: Q1 2026 in Review
Zurich Cantonal Bank increased its Protagonist Therapeutics (PTGX) stake by 33% in Q1 2026, buying an estimated $296K and bringing the position to 13,412 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1229.
Zurich Cantonal Bank first reported a position in PTGX in Q3 2021 and has held it in 19 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- Zurich Cantonal Bank held 13,412 shares of Protagonist Therapeutics worth $1.41M as of Q1 2026.
- Zurich Cantonal Bank bought 3,339 Protagonist Therapeutics shares in Q1 2026, an estimated $296K.
- Protagonist Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1229 holding.
- Zurich Cantonal Bank first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 19 quarters since.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.